Flavone acetic acid potentiates the induction of endothelial procoagulant activity by tumour necrosis factor

J. Clifford Murray, K. Anne Smith, David Stern

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Treatment of human umbilical vein endothelial cells with flavone acetic acid (FAA) at 800 μg/ml for 4 h resulted in a 3-11-fold increase in procoagulant activity. This increase was due to enhanced tissue factor expression on the endothelial cell surface, as evidenced by the blocking of the enhanced clotting with antibody to tissue factor, by substitution of normal with factor VII deficient plasma, or by simultaneous treatment of the endothelial cells with cycloheximide or actinomycin D. FAA was not toxic to endothelial cell at concentrations up to 1.6 mg/ml over 4 h. Combined treatment with FAA and tumour necrosis factor α (TNF-α) (100 pg/ml) produced a 675-fold (range 160-1980) increase in tissue factor activity, compared to 5-fold and 50-fold increases for the individual agents respectively. Northern blotting of total RNA from cells treated with the combination of agents or either agent alone, followed by probing with a cDNA to human tissue factor demonstrated a synergistic increase in tissue factor mRNA after combination treatment. In vivo, the combination of FAA and TNF-α could be shown to induce greater growth delay in two murine tumours than would be predicted on the basis of the activity of either agent alone.

Original languageEnglish (US)
Pages (from-to)765-770
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume27
Issue number6
DOIs
StatePublished - Jan 1 1991

Fingerprint

flavone acetic acid
Thromboplastin
Tumor Necrosis Factor-alpha
Endothelial Cells
Factor VII
Poisons
Human Umbilical Vein Endothelial Cells
Dactinomycin
Cycloheximide
Northern Blotting
Complementary DNA
RNA
Messenger RNA
Antibodies
Growth

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Flavone acetic acid potentiates the induction of endothelial procoagulant activity by tumour necrosis factor. / Clifford Murray, J.; Anne Smith, K.; Stern, David.

In: European Journal of Cancer and Clinical Oncology, Vol. 27, No. 6, 01.01.1991, p. 765-770.

Research output: Contribution to journalArticle

@article{a9bccb32baf44121a876500836ce5867,
title = "Flavone acetic acid potentiates the induction of endothelial procoagulant activity by tumour necrosis factor",
abstract = "Treatment of human umbilical vein endothelial cells with flavone acetic acid (FAA) at 800 μg/ml for 4 h resulted in a 3-11-fold increase in procoagulant activity. This increase was due to enhanced tissue factor expression on the endothelial cell surface, as evidenced by the blocking of the enhanced clotting with antibody to tissue factor, by substitution of normal with factor VII deficient plasma, or by simultaneous treatment of the endothelial cells with cycloheximide or actinomycin D. FAA was not toxic to endothelial cell at concentrations up to 1.6 mg/ml over 4 h. Combined treatment with FAA and tumour necrosis factor α (TNF-α) (100 pg/ml) produced a 675-fold (range 160-1980) increase in tissue factor activity, compared to 5-fold and 50-fold increases for the individual agents respectively. Northern blotting of total RNA from cells treated with the combination of agents or either agent alone, followed by probing with a cDNA to human tissue factor demonstrated a synergistic increase in tissue factor mRNA after combination treatment. In vivo, the combination of FAA and TNF-α could be shown to induce greater growth delay in two murine tumours than would be predicted on the basis of the activity of either agent alone.",
author = "{Clifford Murray}, J. and {Anne Smith}, K. and David Stern",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/0277-5379(91)90185-G",
language = "English (US)",
volume = "27",
pages = "765--770",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "6",

}

TY - JOUR

T1 - Flavone acetic acid potentiates the induction of endothelial procoagulant activity by tumour necrosis factor

AU - Clifford Murray, J.

AU - Anne Smith, K.

AU - Stern, David

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Treatment of human umbilical vein endothelial cells with flavone acetic acid (FAA) at 800 μg/ml for 4 h resulted in a 3-11-fold increase in procoagulant activity. This increase was due to enhanced tissue factor expression on the endothelial cell surface, as evidenced by the blocking of the enhanced clotting with antibody to tissue factor, by substitution of normal with factor VII deficient plasma, or by simultaneous treatment of the endothelial cells with cycloheximide or actinomycin D. FAA was not toxic to endothelial cell at concentrations up to 1.6 mg/ml over 4 h. Combined treatment with FAA and tumour necrosis factor α (TNF-α) (100 pg/ml) produced a 675-fold (range 160-1980) increase in tissue factor activity, compared to 5-fold and 50-fold increases for the individual agents respectively. Northern blotting of total RNA from cells treated with the combination of agents or either agent alone, followed by probing with a cDNA to human tissue factor demonstrated a synergistic increase in tissue factor mRNA after combination treatment. In vivo, the combination of FAA and TNF-α could be shown to induce greater growth delay in two murine tumours than would be predicted on the basis of the activity of either agent alone.

AB - Treatment of human umbilical vein endothelial cells with flavone acetic acid (FAA) at 800 μg/ml for 4 h resulted in a 3-11-fold increase in procoagulant activity. This increase was due to enhanced tissue factor expression on the endothelial cell surface, as evidenced by the blocking of the enhanced clotting with antibody to tissue factor, by substitution of normal with factor VII deficient plasma, or by simultaneous treatment of the endothelial cells with cycloheximide or actinomycin D. FAA was not toxic to endothelial cell at concentrations up to 1.6 mg/ml over 4 h. Combined treatment with FAA and tumour necrosis factor α (TNF-α) (100 pg/ml) produced a 675-fold (range 160-1980) increase in tissue factor activity, compared to 5-fold and 50-fold increases for the individual agents respectively. Northern blotting of total RNA from cells treated with the combination of agents or either agent alone, followed by probing with a cDNA to human tissue factor demonstrated a synergistic increase in tissue factor mRNA after combination treatment. In vivo, the combination of FAA and TNF-α could be shown to induce greater growth delay in two murine tumours than would be predicted on the basis of the activity of either agent alone.

UR - http://www.scopus.com/inward/record.url?scp=0025763448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025763448&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(91)90185-G

DO - 10.1016/0277-5379(91)90185-G

M3 - Article

VL - 27

SP - 765

EP - 770

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 6

ER -